The life sciences industry continues to undergo significant transformation, with companies navigating through portfolio risks, pipeline challenges, public policy, and economic uncertainty. Our latest report reflects on mergers and acquisitions (M&A) trends and venture capital (VC) trends over the past year and provides considerations for biopharmaceutical companies heading into 2025. Discover the key insights below:
M&A activity has been subdued relative to 2023 with companies prioritizing growth and innovation
Acquirers continue to target pre-clinical therapeutics within oncology and central nervous systems (CNS) therapeutic areas
Cell and gene therapies (CGT) and anti-drug conjugates (ADCs) continue to be popular technology targets, with mRNA therapies gaining traction
VC dealmaking continues to remain steady, with 2024 deal volume tracking similarly to 2023
VC deals continue to concentrate around early-stage funding, reflecting a focus on novel innovative technologies
Biotech IPOs in 2024 to date have nearly doubled in volume relative to 2023, indicating acclimation to interest rates generally holding steady
Download the Report
ALVAREZ & MARSAL’S GLOBAL TRANSACTION ADVISORY GROUP CONTINUES BUILD OF GLOBAL SENIOR TALENT ROSTER
May 29, 2025
Leading global professional services firm Alvarez & Marsal’s (A&M’s) Global Transaction Advisory Group (Global TAG) announces the appointments of Patrick Daoust as a Managing Director in Canada, based in Montreal, and Giacomo Giobbi as a Managing Director in Italy, based in Milan, as part of the continued expansion of its global senior talent roster.
2025: Infrastructure Investment Outlook in a World in Flux
April 16, 2025
Discover the state of infrastructure investment, as uncertain markets adjust to higher interest rates and cost of capital, and supply chain disruptions.
Private Equity in 2025: Key Takeaways from Actum Group's Private Equity Value Creation Forum
April 10, 2025
As the private equity landscape continues to shift under the weight of geopolitical tensions, rising regulatory demands and rapid technological advances, the question on every investor’s mind is: how do you create value in 2025 and beyond?
ALVAREZ & MARSAL’S GLOBAL TRANSACTION ADVISORY GROUP CONTINUES TO CARVE ITS SHARE OF THE AUSTRALIAN MARKET WITH NEW TOP TALENT
January 30, 2025
Leading global professional services firm Alvarez & Marsal (A&M) announces the appointment of Sydney-based Brett Duell as a Managing Director within its Global Transaction Advisory Group (Global TAG).
